摘要
目的观察重组人血管内皮抑制素(恩度)联合化疗方案对多种恶性复发肿瘤转移灶的疗效及安全性。方法经病理组织学或细胞学检查确诊的晚期复发恶性肿瘤患者6例,均接受恩度联合化疗的方案治疗。按照RESIST标准评价近期疗效,参照KPS评分评价生活质量,按照NCICTC3.0版标准评价不良反应。结果在6例观察的患者中,PR 1例,CR 3例,SD 2例,RR为66.7%(4/6),CBR为100.0%(6/6),未发现与恩度相关的严重不良反应。结论恩度联合化疗的方案对治疗恶性肿瘤患者的复发和转移具有良好的疗效,同时没有明显增加化疗的不良反应,值得进一步推广。
Objective To observe the effects and safety of recombinant human endostatin（Endostar） combination with chemotherapy for the treatment of the metastasis of recurrence malignant tumor.Methods 6 patients with pathologically or cytologically confirmed recurrent or metastatic malignant tumors were treated with Endostar combined with chemotherapy.The treatment results were evaluated according to the RESIST criteria.The KPS scores were used to evaluate the quality of life,and the NCICTC 3.0 was used to evaluate the toxicities.Results Of the 6 patients,there were 1 PR,3 CR,and 2 SD,with an OR rate of 66.7% and CBR rate of 100.0%.Conclusion Endostar combined with chemotherapy was effective in the treatment of patients with recurrent or metastatic malignant tumors without significantly increase of the toxicities of the chemotherapy.
出处
《实用癌症杂志》
2011年第1期69-70,共2页
The Practical Journal of Cancer
关键词
晚期肿瘤
重组人血管内皮抑制素
复发转移
Advanced cancer
Recombinant human endostatin
Recurrence and metastasis
